Immunovant - 53 Year Dividend History | IMVT

Historical dividend payout and yield for Immunovant (IMVT) since 1971. The current TTM dividend payout for Immunovant (IMVT) as of May 17, 2024 is $0.00. The current dividend yield for Immunovant as of May 17, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.574B $0.000B
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.
Stock Name Country Market Cap PE Ratio